Company · CIK 0001689375 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Entrada Therapeutics, Inc. · TRDA
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 SForm 4 → | Sep 9, 7:24 pm EDT | MPM BIOVENTURES 2018, L.P. +210% Owner | 259,837 | $7.33 | $1,905,768 | 3,885,115 | −6.27% | |
| Sep 4, 2026 SForm 4 → | Sep 9, 7:23 pm EDT | MPM BioVentures 2014, L.P. +910% Owner | 259,837 | $7.33 | $1,905,768 | 3,885,115 | −6.27% | |
| Sep 2, 2026 FForm 4 → | Sep 3, 5:19 pm EDT | Dipal DoshiCEO, Director | 8,724 | $7.14 | $62,323 | 517,290 | — | |
| Sep 2, 2026 FForm 4 → | Sep 3, 5:18 pm EDT | Nathan J DowdenPresident & COO | 2,528 | $7.14 | $18,060 | 196,060 | — | |
| Sep 2, 2026 FForm 4 → | Sep 3, 5:16 pm EDT | Natarajan SethuramanPresident, Research & Develop. | 2,079 | $7.14 | $14,852 | 214,238 | — | |
| Sep 2, 2026 FForm 4 → | Sep 3, 5:15 pm EDT | Kory James WentworthChief Financial Officer | 1,733 | $7.14 | $12,380 | 117,277 | — | |
| Sep 1, 2026 SForm 4 → | Sep 3, 7:21 pm EDT | MPM BIOVENTURES 2018, L.P. +210% Owner | 86,482 | $7.14 | $617,379 | 4,144,952 | −2.04% | |
| Sep 1, 2026 SForm 4 → | Sep 3, 7:21 pm EDT | MPM BioVentures 2014, L.P. +910% Owner | 86,482 | $7.14 | $617,379 | 4,144,952 | −2.04% |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.